Amphastar Pharmaceuticals Inc (AMPH) valuation
Amphastar Pharmaceuticals P/E ratio history
Amphastar Pharmaceuticals trades at 16.4 times its earnings over the last twelve months and 9.9 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 12.1 (year to Dec 2024) to 240.5 (year to Dec 2017), with a median of 19.1.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $26.78 | $2.03 | 13.2 | 7.5 |
| Dec 31, 2024 | $37.13 | $3.06 | 12.1 | 8.8 |
| Dec 31, 2023 | $61.85 | $2.60 | 23.8 | 17.1 |
| Dec 31, 2022 | $28.02 | $1.74 | 16.1 | 15.0 |
| Dec 31, 2021 | $23.29 | $1.25 | 18.6 | — |
| Dec 31, 2020 | $20.11 | $0.03 | n/m | — |
| Dec 31, 2019 | $19.29 | $0.99 | 19.5 | — |
| Dec 31, 2018 | $19.90 | -$0.12 | n/m | — |
| Dec 31, 2017 | $19.24 | $0.08 | 240.5 | — |
| Dec 31, 2016 | $18.42 | $0.22 | 83.7 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Amphastar Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Amphastar PharmaceuticalsAMPH | $1.22B | 16.4 | 9.9 | 1.7 |
| Staar SurgicalSTAA | $1.22B | 306.8 | 25.1 | 3.6 |
| Syndax PharmaceuticalsSNDX | $1.21B | — | — | 4.8 |
| Rapport TherapeuticsRAPP | $1.20B | — | — | 59.9 |
| Innovage HoldingINNV | $1.25B | — | 20.4 | 1.3 |
| Opko HealthOPK | $1.25B | — | — | 2.1 |
| Tyra BiosciencesTYRA | $1.25B | — | — | — |
| Taysha Gene TherapiesTSHA | $1.19B | — | — | 216.4 |
| EnovisENOV | $1.15B | — | 5.6 | 0.5 |
| Peer median | 306.8 | 20.4 | 3.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: AMPH financials · AMPH returns
No forecast, no recommendation. This page describes Amphastar Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.